Skip to content
#Pharma #Digitalization​

Syntegon delivers strong growth and EBITDA improvements in the first half of 2025

| 3 min read

Syntegon startet 2025 mit Rückenwind: Wachstum und Profitabilität ziehen an, getragen vom Pharmageschäft; die gloveless RTU-Lösung „SynTiso“ unterstreicht den Innovationskurs und stützt einen positiven Ausblick.

blog-hero-banner
Contents

    Headline H4 for main headlines

    Lorem ipsum dolor sit amet, bold highlighting in the text, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore text link in content erat, sed diam voluptua.

    Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Bold highlight sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua.

    Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum.

    Learn more

    Headline H5 for Subheadlines

    Stuttgart (Germany), September 02, 2025 – The Syntegon Group, a leading strategic partner to the global pharmaceutical, biotech and food industries, reported strong results for the first half year of 2025 compared to the prior year. Driven by the growth-focused strategy launched in 2024, the Group delivered double-digit sales growth, significantly higher profitability, and strong free cash flow, while continuing to advance on its strategic agenda.

    • Successful growth strategy delivers sales growth in H1 of +11% versus prior year to €824m
    • Strong growth momentum in the Pharma segment
    • EBITDA up +41% to €127m, with margin expanding 300 bps to 15.5%.
    • Free cash flow €63m, +11% above 2024’s high benchmark
    • H1 Book-to-Bill at 117%, signaling strong foundation for future growth
    • 2025 outlook: sustained sales growth and continued margin expansion
    Learn more

    Headline H5 for Subheadlines

    Stuttgart (Germany), September 02, 2025 – The Syntegon Group, a leading strategic partner to the global pharmaceutical, biotech and food industries, reported strong results for the first half year of 2025 compared to the prior year. Driven by the growth-focused strategy launched in 2024, the Group delivered double-digit sales growth, significantly higher profitability, and strong free cash flow, while continuing to advance on its strategic agenda.

    Links to important pages of Syntegon
    Discover our careers
    Discover our food automation solutions
    • Important Fact or Figure lorem ipsum dolor
    • Important Fact or Figure lorem ipsum dolor
    • Important Fact or Figure lorem ipsum dolor
    • Important Fact or Figure lorem ipsum dolor
    • Important Fact or Figure lorem ipsum dolor
    • Important Fact or Figure lorem ipsum dolor

    Highlight Information / Question

    Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.

    Key Takeaways

    • Successful growth strategy delivers sales growth in H1 of +11% versus prior year to €824m
    • Strong growth momentum in the Pharma segment
    • EBITDA up +41% to €127m, with margin expanding 300 bps to 15.5%.; all business units contributing
    • Free cash flow €63m, +11% above 2024’s high benchmark
    • H1 Book-to-Bill at 117%, signaling strong foundation for future growth
    • 2025 outlook: sustained sales growth and continued margin expansion

    Syntegon Newsletter

    Get inspired with regular updates on technologies and services, case studies, webinar offers and events.

    Subscribe
    blog-media

    Image caption goes here Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat

    quote

    With strong order intake and top line growth, improved margins across all business units, and continued operational efficiency gains, Syntegon is well on track to deliver another year of record results.

    Torsten Tuerling | CEO of Syntegon

    quote

    With strong order intake and top line growth, improved margins across all business units, and continued operational efficiency gains, Syntegon is well on track to deliver another year of record results.

    Torsten Tuerling | CEO of Syntegon

    With strong order intake and top line growth, improved margins across all business units, and continued operational efficiency gains, Syntegon is well on track to deliver another year of record results.

    Torsten Tuerling | CEO of Syntegon

    Aspen Pharmacare: Covid-19 vaccine retrofit in record time
    Aspen Pharmacare: Covid-19 vaccine retrofit in record time

    Aspen transformed its SVP line “Alice” into a 24/7 vaccine filler – thanks to Syntegon’s fast retrofit, embedded service, and flexible equipment.

    Download
    Aspen Pharmacare: Covid-19 vaccine retrofit in record time
    Aspen Pharmacare: Covid-19 vaccine retrofit in record time

    Aspen transformed its SVP line “Alice” into a 24/7 vaccine filler – thanks to Syntegon’s fast retrofit, embedded service, and flexible equipment.

    Download
    Still have questions?

    Still have questions?

    We are happy to help.
    Worldwide contacts

    Discover more about Syntegon

    TEST 2025
    TEST 2025

    DADA

    Learn more
    New SynTiso line concept from Syntegon revolutionizes liquid pharmaceutical filling
    New SynTiso line concept from Syntegon revolutionizes liquid pharmaceutical filling

    Joint development with partners from the pharmaceutical industry. The highest output in the market: up to 600 containers per minute. Significantly reduced contamination risk thanks to full automation...

    Learn more
    Syntegon reports strong sustainability progress in 2024 and sets ambitious climate targets
    Syntegon reports strong sustainability progress in 2024 and sets ambitious climate targets

    2024 sustainability report highlights tangible sustainability gains across emissions, energy, and circularity. Sustainable solutions are a key pillar of the corporate strategy. EcoVadis platinum...

    Learn more